Galleon Pharmaceuticals is hoping to be in mid-stage clinical testing in humans for a sleep apnea pill by mid-2015, reports Philadelphia Business Journal.
Galleon’s research team, which includes scientists from Merck, Cephalon, and Schering, spent five years developing its technology and screening hundreds of compounds before deciding to develop two new drug candidates. Those experimental therapies are GAL-160, the oral medicine for sleep apnea, and GAL-021, an intravenous drug being developed to treat respiratory complications in hospitalized patients receiving anesthetics and opioid pain medicines.
